Krüger A, Wollny M, Oberkircher L, Bornemann R, Pflugmacher R
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Gießen und Marburg GmbH, Marburg.
Z Orthop Unfall. 2012 Oct;150(5):539-46. doi: 10.1055/s-0032-1315287. Epub 2012 Oct 17.
If clearly indicated and implemented, augmentations of vertebral bodies with cement are standardized, safe and low-risk procedures. However, the multiplicity of providers and systems are today more varied than ever. At present, the systems differ starkly from one another not only in specifications, possible applications and extensions of indications, but they are also extremely variable in price. Publications have shown that in times of medical-economic change, vertebral augmentations make sense not only medically, but also in terms of economics and the national economy. Our analysis targets the question of how insurance costs with vertebroplasty and kyphoplasty affect profit margins per G-DRG (German Diagnosis Related Groups) in consideration of the different system approaches of the providers.
After reviewing the literature, extremely varied, minimally invasive augmentation methods and techniques for treating vertebral body fractures were identified and classified. These were grouped based also [sic: on] OPS and possibly further subdivisions. Material costs were gathered based on average price quotations of different providers and techniques and aligned with those from the literature. The inpatient costs per day were estimated as a lump sum according to published information, since our analysis was interested in less detailed process costs as these are difficult to transfer to other clinics due to parameters being unique to each facility. The G-DRGs concerned were likewise determined according to the case-based lump sum catalogue from 2012. Based on this, the material costs as well as the daily costs per day of inpatient stay according to the average length of stay per G-DRG were subtracted.
Vertebral augmentation methods are classified into vertebroplasty and kyphoplasty according to OPS. In addition, according to current literature, a further subdivision of kyphoplasty into substance-conserving or direct cement injection techniques and substance-destroying or indirect cement injection techniques took place. The procedures involve material costs between 10-40 % of G-DRG revenue. The profit margin of vertebral augmentation ranges from approx. 4100 € to approx. 11 400 €. The calculative costs of the inpatient care per day amount to 488.86 €. Based on the average lengths of stay per G-DRG (7.8-12.6 days) for 2012 determined by the InEK (Institut für das Entgeltsystem im Krankenhaus [Institute for the Hospital Remuneration System]), the financial costs of inpatient care were calculated between 3813.11 € and 6159.65 €. A shortfall of -197.53 € for the treatment of a vertebral body resulted for the vertebroplasty. This shortfall increases with the treatment of three vertebral bodies and a PCCL = 4 to -466.30 €. The indirect cement injection techniques accounted for a positive profit margin of 196.03 € for the treatment of a vertebra. Due to high material costs, however, this dips into the negative in the amount of -1227.70 € for two vertebrae and increases to -2522.50 € for the treatment of three vertebral bodies. In contrast, the multilevel care in substance-preserving kyphoplasty techniques show a positive profit margin of 72.30 € for the treatment of two vertebrae and 577.50 € for the treatment of three vertebrae.
Against the background of the increasing economization of the health care system, it should be emphasized once more that the decision for a therapy or a system based on medical reasons should only be made by the treating physician. The vertebroplasty could not be performed at a profit in our analysis, despite comparatively low material costs. A shortfall between -197.53 € and -466.30 € was determined. The comparatively higher material costs of the kyphoplasty make comparisons important. The results of our investigation also show that supposedly inexpensive purchases of materials are not automatically a favorable alternative. In addition, the kyphoplasty techniques currently available on the market are not necessarily comparable. According to our investigation, profits of between 196.03 € and 577.50 € are to be realized in the selection of vertebral augmentation systems based on purely economic considerations. The results of our analysis show that the pure comparison of figures of the average material costs of a G-DRG and the material price distort the picture. A calculation of the profit margin on the basis of costs of care per vertebral body is more definitive.
如果有明确指征并得以实施,椎体骨水泥强化术是标准化、安全且低风险的手术。然而,如今提供此类手术的机构和系统种类比以往任何时候都更加多样。目前,这些系统不仅在规格、可能的应用范围和适应症扩展方面差异巨大,而且价格也极为多变。有出版物表明,在医疗经济变革时期,椎体强化术不仅在医学上有意义,在经济和国民经济方面也有意义。我们的分析旨在探讨椎体成形术和后凸成形术的保险费用如何影响每个德国诊断相关分组(G-DRG)的利润率,同时考虑到不同供应商的系统方法。
在查阅文献后,确定并分类了用于治疗椎体骨折的极为多样的微创强化方法和技术。这些方法还根据德国医疗程序编码(OPS)及可能的进一步细分进行了分组。根据不同供应商和技术的平均报价收集材料成本,并与文献中的数据进行比对。根据已发表的信息,将住院每日费用估算为一个总计金额,因为我们的分析关注的是不太详细的过程成本,由于每个机构的参数独特,这些成本难以转移到其他诊所。相关的G-DRG同样根据2012年的病例总计目录确定。在此基础上,减去材料成本以及根据每个G-DRG的平均住院天数计算的每日住院费用。
根据OPS,椎体强化方法分为椎体成形术和后凸成形术。此外,根据当前文献,后凸成形术进一步细分为保留骨质或直接骨水泥注射技术以及破坏骨质或间接骨水泥注射技术。这些手术的材料成本占G-DRG收入的10 - 40%。椎体强化术的利润率约为4100欧元至约11400欧元。住院护理的计算成本为每日488.86欧元。根据医院报销系统研究所(InEK)确定的2012年每个G-DRG的平均住院天数(7.8 - 12.6天),计算出住院护理的财务成本在3813.11欧元至6159.65欧元之间。椎体成形术治疗一个椎体出现-197.53欧元的亏损。随着治疗三个椎体且PCCL = 4,亏损增加至-466.30欧元。间接骨水泥注射技术治疗一个椎体的利润率为正196.03欧元。然而,由于材料成本高昂,治疗两个椎体时利润率降至-1227.70欧元,治疗三个椎体时增加至-2522.50欧元。相比之下,保留骨质的后凸成形术技术的多级护理在治疗两个椎体时利润率为正72.30欧元,治疗三个椎体时为577.50欧元。
在医疗保健系统日益经济化的背景下,应再次强调,基于医学原因选择治疗方法或系统的决策只能由主治医生做出。在我们的分析中,尽管材料成本相对较低,但椎体成形术无法实现盈利。确定的亏损在-197.53欧元至-466.30欧元之间。后凸成形术相对较高的材料成本使得比较变得重要。我们的调查结果还表明,看似廉价的材料采购不一定是有利的选择。此外,目前市场上的后凸成形术技术不一定具有可比性。根据我们的调查,基于纯粹经济考虑选择椎体强化系统时,可实现196.03欧元至577.50欧元的利润。我们的分析结果表明,单纯比较G-DRG的平均材料成本数字和材料价格会扭曲实际情况。基于每个椎体护理成本计算利润率更具决定性。